Dr. Fouad M. Hajjar
Claim this profileAdventHealth Orlando
Expert in Cancer
Expert in Neuroblastoma
46 reported clinical trials
89 drugs studied
About Fouad M. Hajjar
Education:
- Obtained MD from the American University of Beirut Faculty of Medicine, Lebanon, in 1987.
- Completed Residency in Internal Medicine at the University of Florida College of Medicine, Gainesville, FL, in 1990.
- Finished Fellowship in Cardiovascular Disease at the University of Florida College of Medicine, Gainesville, FL, in 1993.
Experience:
- Currently serves as a cardiologist at AdventHealth Orlando.
- Holds a position as an Assistant Professor of Medicine at the University of Central Florida College of Medicine.
Area of expertise
1Cancer
Global LeaderStage I
Stage II
Stage IV
2Neuroblastoma
Global LeaderStage IV
MYC positive
MYC negative
Affiliated Hospitals
Clinical Trials Fouad M. Hajjar is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
More about Fouad M. Hajjar
Clinical Trial Related8 years of experience running clinical trials · Led 46 trials as a Principal Investigator · 13 Active Clinical TrialsTreatments Fouad M. Hajjar has experience with
- Cyclophosphamide
- Etoposide
- Vincristine Sulfate
- Radiation Therapy
- Mercaptopurine
- Methotrexate
Breakdown of trials Fouad M. Hajjar has run
Cancer
Neuroblastoma
Brain Tumor
Brain Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Fouad M. Hajjar specialize in?
Fouad M. Hajjar focuses on Cancer and Neuroblastoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage II.
Is Fouad M. Hajjar currently recruiting for clinical trials?
Yes, Fouad M. Hajjar is currently recruiting for 13 clinical trials in Orlando Florida. If you're interested in participating, you should apply.
Are there any treatments that Fouad M. Hajjar has studied deeply?
Yes, Fouad M. Hajjar has studied treatments such as Cyclophosphamide, Etoposide, Vincristine Sulfate.
What is the best way to schedule an appointment with Fouad M. Hajjar?
Apply for one of the trials that Fouad M. Hajjar is conducting.
What is the office address of Fouad M. Hajjar?
The office of Fouad M. Hajjar is located at: AdventHealth Orlando, Orlando, Florida 32803 United States. This is the address for their practice at the AdventHealth Orlando.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.